A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

Inclusion Criteria: * HIV-1 seropositive adults must satisfy all the following inclusion criteria to be eligible for the study: * Aged 18 to 60 years (inclusive) * Resident in or near the trial sites for the duration of the vaccination study for the participant * Able and willing (in the Investigator's opinion) to comply with all study requirements * HIV Viral Load \<50 copies/mL at the last routine HIV follow-up visit within the last 9 months prior to inclusion whilst on treatment with an effective ART regimen * Willingness to remain on ART for the study duration * CD4 cell count above 350 cells/uL * Negative HCV serology and negative HCV RNA polymerase chain reaction (PCR) testing * For women of child bearing potential, willingness to practise continuous effective contraception during the study and a negative pregnancy test on the day(s) of vaccination. Effective contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. In subjects on ART, these are: * Injectable progestogen * Male partner sterilisation prior to the female subject's entry into the study, and this male is the sole partner for that subject * Male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository) * Intrauterine device or intrauterine system * In addition male partners should use condoms until 3 months after th…